SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference
SeaStar Medical (Nasdaq: ICU), a commercial-stage healthcare company specializing in treatments for critically ill patients with organ failure, announced its participation in the HC Wainwright 27th Annual Global Investment Conference.
The company's presentation is scheduled for September 5, 2025, at 7:00 am ET. Investors can access the presentation through the Events & Presentations page in the Investor Relations section of SeaStar Medical's website, where it will remain available for 60 days after the event.
SeaStar Medical (Nasdaq: ICU), azienda sanitaria in fase commerciale specializzata nei trattamenti per pazienti critici con insufficienza d'organo, ha annunciato la propria partecipazione alla HC Wainwright 27th Annual Global Investment Conference.
La presentazione 猫 in programma per il 5 settembre 2025 alle 7:00 ET. Gli investitori potranno visualizzarla nella pagina Events & Presentations, nella sezione Investor Relations del sito di SeaStar Medical; sar脿 disponibile per 60 giorni dopo l'evento.
SeaStar Medical (Nasdaq: ICU), una compa帽铆a sanitaria en fase comercial especializada en tratamientos para pacientes cr铆ticos con fallo org谩nico, anunci贸 su participaci贸n en la HC Wainwright 27th Annual Global Investment Conference.
La presentaci贸n est谩 programada para el 5 de septiembre de 2025 a las 7:00 ET. Los inversores podr谩n acceder a la presentaci贸n en la p谩gina Events & Presentations de la secci贸n Investor Relations del sitio web de SeaStar Medical; permanecer谩 disponible durante 60 d铆as despu茅s del evento.
SeaStar Medical (Nasdaq: ICU)電� 鞛リ赴攵�鞝勳溂搿� 鞙勳頃� 頇橃瀽 旃橂毳� 鞝勲鞙茧 頃橂姅 靸侅梾 雼硠鞚� 鞚橂 旮办梾鞙茧, HC Wainwright 27th Annual Global Investment Conference鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
须岇偓电� 2025雲� 9鞗� 5鞚� 鞓れ爠 7:00 ET鞐� 頂勲爤鞝犿厡鞚挫厴鞚� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 韴瀽鞛愲摛鞚� SeaStar Medical 鞗轨偓鞚错姼鞚� Investor Relations 靹轨厴 雮� Events & Presentations 韼橃澊歆�鞐愳劀 鞛愲鞐� 鞝戩啀頃� 靾� 鞛堨溂氅�, 鞚措菠韸� 頉� 60鞚� 霃欖晥 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟.
SeaStar Medical (Nasdaq: ICU), entreprise en phase commerciale sp茅cialis茅e dans les traitements des patients en 茅tat critique atteints d'insuffisance organique, a annonc茅 sa participation 脿 la HC Wainwright 27th Annual Global Investment Conference.
La pr茅sentation est pr茅vue le 5 septembre 2025 脿 7h00 ET. Les investisseurs pourront consulter la pr茅sentation sur la page Events & Presentations de la section Investor Relations du site de SeaStar Medical ; elle restera disponible pendant 60 jours apr猫s l'茅v茅nement.
SeaStar Medical (Nasdaq: ICU), ein Unternehmen in der kommerziellen Phase, das sich auf Behandlungen f眉r kritisch kranke Patienten mit Organversagen spezialisiert hat, gab seine Teilnahme an der HC Wainwright 27th Annual Global Investment Conference bekannt.
Die Pr盲sentation ist f眉r den 5. September 2025 um 7:00 Uhr ET angesetzt. Investoren k枚nnen die Pr盲sentation auf der Seite Events & Presentations im Investor-Relations-Bereich der SeaStar Medical-Website abrufen; sie wird nach der Veranstaltung f眉r 60 Tage verf眉gbar bleiben.
- None.
- None.
DENVER, Sept. 04, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today its participation in the upcoming HC Wainwright 27th Annual Global Investment Conference.
The SeaStar Medical presentation can be viewed on Friday, September 5, 2025, at 7:00 am Eastern Time. The presentation can be accessed by visiting the , located under the Investor Relations section of the , and will be available for 60 days following the presentation.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The therapy is SeaStar Medical鈥檚 first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. It was approved in 2024 by the U.S. Food and Drug Administration (FDA). QUELIMMUNE is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar鈥檚 Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the US annually.
For more information visit or visit us on or .
颁辞苍迟补肠迟:鈥�
FAQ
When is SeaStar Medical (ICU) presenting at the HC Wainwright Conference?
How can investors access SeaStar Medical's HC Wainwright Conference presentation?
How long will SeaStar Medical's HC Wainwright presentation be available online?
What is SeaStar Medical's (ICU) business focus?
